Anavex Life Sciences (AVXL) Reports Q3 Loss of $0.06/Share; No Longer Under SEC Investigation

Anavex Life Sciences (NASDAQ: AVXL) reported Q3 EPS of ($0.06), versus ($0.22) reported last year.

The SEC staff recently advised Company’s legal counsel that the staff did not intend to recommend enforcement action by the Commission against the Company in connection with the investigation previously described in the Company’s 2015 Report on Form 10-K.

For earnings history and earnings-related data on Anavex Life Sciences (AVXL) click here.

You May Also Be Interested In

• Optimum Communications gets NYSE non-compliance notice over stock price
• Allarity reports Q2 2026 results, completes stenoparib manufacturing
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c